Ebos lifted profit 21% in FY22 but analysts are asking how long it can last

Ebos lifted profit 21% in FY22 but analysts are asking how long it can last
Chief executive John Cullity said covid could be a tailwind or a headwind by the end of FY23. (Photo: Ebos)
Dan Brunskill
Ebos Group’s annual revenue has climbed above A$10 billion (NZ$11.15b) as the pandemic has increased demand for pharmaceutical products, but analysts are asking if that trend could reverse.  The healthcare and animal products company has been a beneficiary of the covid-19 pandemic, growing its revenue from A$8.7b in 2020 to A$10.7b in 2022.This year alone it grew revenue by 16.6%, underlying earnings by 19% and underlying net profit by 21.3% to A$228.2 million.Not all the growth has been driven by the pandemic however, Forsyth Barr r...

More Markets

NZ sharemarket starts week down 0.8%
Markets Market Close

NZ sharemarket starts week down 0.8%

The S&P/NZX 50 Index closed at 13,351.92, down 115.34 points or 0.86%.

Graham Skellern 13 Oct 2025
ANZ NZ continues to hold market-leading position: ANZ Group
Finance

ANZ NZ continues to hold market-leading position: ANZ Group

ANZ NZ holds market-leading position, continues re-platforming: ANZ Group 

Staff reporters 13 Oct 2025
Trump's trade war hits the NZX
Markets

Trump's trade war hits the NZX

The kiwi dollar fell to a six-month low against the greenback. 

Rebecca Howard 13 Oct 2025